|
rs1555206402
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1529909
|
|
|
0.010 |
GeneticVariation |
BEFREE |
101 hypertensive patients with hyperuricemia were detected the genotypes of URAT1 rs1529909 and rs3825016 and undergo a 2-weeks following losartan treatment.
|
26086348 |
2015 |
|
rs4994
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Trp64Arg polymorphism of the beta-3 adrenergic receptor may be independently associated with hyperuricemia in males.
|
17225053 |
2007 |
|
rs4994
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Trp64Arg polymorphism of the ADRB3 gene predicted the risk of developing hyperuricemia in this adult population.
|
20008926 |
2010 |
|
rs4994
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Trp64Arg polymorphism was associated with hyperuricemia in a Chinese male population and should be an independent risk factor for hyperuricemia.
|
23729572 |
2013 |
|
rs4148500
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A total of 39 common variants were detected, with an ABCC4 variant (rs4148500) significantly associated with hyperuricemia and gout.
|
28371506 |
2017 |
|
rs72552713
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Adenosine 5'-triphosphate-binding cassette subfamily G member 2 (ABCG2) is a urate transporter, and common dysfunctional variants of ABCG2, non-functional Q126X (rs72552713) and semi-functional Q141K (rs2231142), are risk factors for hyperuricemia and gout.
|
29342419 |
2018 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Adenosine 5'-triphosphate-binding cassette subfamily G member 2 (ABCG2) is a urate transporter, and common dysfunctional variants of ABCG2, non-functional Q126X (rs72552713) and semi-functional Q141K (rs2231142), are risk factors for hyperuricemia and gout.
|
29342419 |
2018 |
|
rs1217691063
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Although the mechanism of the relationship between the C677T polymorphism and uric acid still remains unclear, these original articles showed that the MTHFR C677T polymorphism may be an independent risk factor for hyperuricemia.
|
22286863 |
2012 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Associations of the rs2231142 variant with serum uric acid levels and prevalence of gout and hyperuricaemia were examined.
|
20421215 |
2010 |
|
rs1822825
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BMI, gender, and the rs1822</span>825 polymorphism in the PPARγ gene appeared good biomarkers in hyperuricemia; therefore, these powerful indicators may be included in the prediction of hyperuricemia</span> to increase the accuracy of the analysis.
|
23237621 |
2013 |
|
rs671
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Both rs671 major G allele and wGRS were not associated with hyperuricemia.
|
31338989 |
2019 |
|
rs5443
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Despite the sufficient statistical power, this study could not demonstrate the significant influence of C825T on hyperuricemia or serum uric acid.
|
16707857 |
2006 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Finally, we have demonstrated the utility of using small molecules to correct the Q141K defect in expression and function as a possible therapeutic approach for hyperuricemia and gout.
|
23493553 |
2013 |
|
rs187238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For the Kazak population, only IL-18 rs187238 showed statistical significance with hyperuricemia (P=0.002 by genotype and P=0.007, OR 1.823 by allele).
|
26722554 |
2015 |
|
rs4073
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For the Uygur population, IL-8 rs4073, IL-18 rs187238 and IL-18RAP rs130154 polymorphisms were all associated with hyperuricemia (P<0.001 by genotype and P=0.008, OR 0.802 by allele for IL-8; P=0.01 by genotype and P=0.006, OR 1.332 by allele for IL-18 rs187238; P=0.007 by genotype and P=0.005, OR 1.27 by allele for IL-18RAP rs130154).
|
26722554 |
2015 |
|
rs130154
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For the Uygur population, IL-8 rs4073, IL-18 rs187238 and IL-18RAP rs130154 polymorphisms were all associated with hyperuricemia (P<0.001 by genotype and P=0.008, OR 0.802 by allele for IL-8; P=0.01 by genotype and P=0.006, OR 1.332 by allele for IL-18 rs187238; P=0.007 by genotype and P=0.005, OR 1.27 by allele for IL-18RAP rs130154).
|
26722554 |
2015 |
|
rs11554266
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs138551969
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs141158222
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs141310123
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs142226072
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs143231463
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs143583842
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs143709408
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |